Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

angible asset, net 12,387 13,548 Property and equipment, net 13,238 15,460 Marketable securities, non-current 3,145 23,882 Other assets 969 3,931 Total assets $79,780 $160,540 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable and accrued expenses $13,136 $21,809 Deferred revenue, related party 5,965 8,372 Other current liabilities 475 553 Total current liabilities 19,576 30,734 Long-term obligations 17,061 19,107 Deferred revenue, related party, net of current portion 35,790 41,861 Total liabilities 72,427 91,702 Stockholders' equity 7,353 68,838 Total liabilities and stockholders' equity $79,780 $160,540

    Idenix Pharmaceuticals' Contacts:
    Media: Teri Dahlman (617) 995-9905
    Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical ... cell therapies, announced today that RepliCel,s CEO, David Hall ... Minneapolis, Minnesota on August 5 th ... RepliCel,s 18-month milestones including CE Mark for its RCI-02 dermal ... data from both RCT-01 (tendon) and RCS-01 (skin) clinical trials ...
(Date:7/31/2015)... 31, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has filed its Annual ... Exchange Commission. The filed Form 20-F includes audited financial ... The Form 20-F can be accessed by visiting the ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
Breaking Biology Technology:RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: ... its fourth quarter and fiscal year 2008 on December 11, 2008, ... at 4:45 p.m. ET Martek will conduct a conference call to ... to the call live via webcast by visiting Martek,s web site ...
... Early to Mid-2009 , , ... the proprietary products division of Par Pharmaceutical Companies, Inc. ... development partner, MonoSol Rx, reported the successful completion of ... of ondansetron. The ondansetron thin film product is being ...
... (BCI), a,biopharmaceutical company utilizing its platform technology to ... new neurons for the treatment of,central nervous system ... Thompson to its board of directors. Thompson is ... tenure at Eli Lilly and Co. where he,focused ...
Cached Biology Technology:Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 2Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 4BrainCells Inc. Appoints David E. Thompson to Its Board of Directors 2BrainCells Inc. Appoints David E. Thompson to Its Board of Directors 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... COLUMBUS, Ohio Very few athletic trainers associated with ... were following best practice standards for managing asthma among ... athletes with asthma, the dangers of the condition can ... severe to be incapacitating, or deadly. The lead report ...
... and inanimate phenomena may have more in common than previously ... University engineer Adrian Bejan and Penn State biologist James Marden. ... theory that flow systems from animal locomotion to the ... and minimize imperfections. Flows evolve to reduce friction or other ...
... Conan Doyle,s account of an isolated community of dinosaurs that ... no less appeal now than it did when it was ... recreate the lost world of dinosaurs, but today the fiction ... suggests that dinosaur bones from the Ojo Alamo Sandstone in ...
Cached Biology News:Athletes with asthma need more help from their team trainers 2Unifying the animate and the inanimate designs of nature 2Evidence of the 'Lost World' -- did dinosaurs survive the end Cretaceous extinctions? 2
... enclosures are designed for ... other process gas to ... HEPA filtration, heating/cooling, humidification, ... also available, along with ...
... the professional, student, or faculty researcher, the new ... your research and improve the quality of your ... the edge that researchers using LI-COR DNA analysis ... The 4300 System is a third generation instrument ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... determined by Biuret. Physical form: ... 4 ) 2 SO 4 ... Affinity purified • Physical Form: ... MgCl 2 1 ZnCl ...
Biology Products: